LS CancerDiag

Rank S100 index Change Change %   Business ID
514. (-25) 241 -15 -5.88 % 2558287-9

Founded: 2013 Category: HealthTech City: Helsinki

LS CancerDiag Ltd is committed to reducing cancer mortality rates with a simple diagnostic method that reliably detects an inherited cancer-causing condition prior to cancer. Our vision is to see DiagMMR® as the new Gold Standard for Lynch syndrome detection. Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS. Our groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary Non­Polyposis Colorectal Cancer; HNPCC). Our mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome globally by delivering predictive and accurate results with a fast, unique and cost-efficient method.


News feed